182 related articles for article (PubMed ID: 33863896)
41. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
Gampenrieder SP; Rinnerthaler G; Tinchon C; Petzer A; Balic M; Heibl S; Schmitt C; Zabernigg AF; Egle D; Sandholzer M; Singer CF; Roitner F; Hager C; Andel J; Hubalek M; Knauer M; Greil R
Breast Cancer Res; 2021 Dec; 23(1):112. PubMed ID: 34906198
[TBL] [Abstract][Full Text] [Related]
42. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.
Yang YF; Liao YY; Yang M; Peng NF; Xie SR; Xie YF
Med Oncol; 2014 Oct; 31(10):214. PubMed ID: 25216864
[TBL] [Abstract][Full Text] [Related]
43. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Cabel L; Carton M; Cheaib B; Pierga JY; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Desmoulins I; Lefeuvre C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Perrocheau G; Piot I; Pérol D; Simon G; Lerebours F
Breast Cancer Res Treat; 2019 Jan; 173(2):397-406. PubMed ID: 30357526
[TBL] [Abstract][Full Text] [Related]
44. Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.
van Es SC; van der Vegt B; Bensch F; Gerritse S; van Helden EJ; Boon E; Angus L; Overbosch J; Menke-van der Houven van Oordt CW; Verheul HM; van Herpen CML; Jager A; Oosting SF; de Vries EGE; Schröder CP
Am J Surg Pathol; 2019 Oct; 43(10):1355-1360. PubMed ID: 31283631
[TBL] [Abstract][Full Text] [Related]
45. Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance.
Kotecha R; Tonse R; Rubens M; McDermott MW; Odia Y; Appel H; Mehta MP
Neurooncol Adv; 2021; 3(1):vdab010. PubMed ID: 33898990
[TBL] [Abstract][Full Text] [Related]
46. Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice.
Brufsky A; Liu X; Li B; McRoy L; Layman RM
Target Oncol; 2021 Sep; 16(5):601-611. PubMed ID: 34338965
[TBL] [Abstract][Full Text] [Related]
47. Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort.
Hotton J; Lusque A; Leufflen L; Campone M; Levy C; Honart JF; Mailliez A; Debled M; Gutowski M; Leheurteur M; Goncalves A; Jankowski C; Guillermet S; Bachelot T; Ferrero JM; Eymard JC; Petit T; Pouget N; de La Lande B; Frenel JS; Villacroux O; Simon G; Pons-Tostivint E; Marchai F
Ann Surg; 2023 Jan; 277(1):e153-e161. PubMed ID: 33534229
[TBL] [Abstract][Full Text] [Related]
48. Clinical importance of discordance of hormone receptors and Her2/neu status after neoadjuvant chemotherapy in breast cancer.
Basak Oven Ustaalioglu B; Aker Vardar F; Bilici A; Gurleyik G; Erkol B; Kefeli U; Aliustaoglu M
J BUON; 2014; 19(4):879-86. PubMed ID: 25536590
[TBL] [Abstract][Full Text] [Related]
49. Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China.
Yang J; Zhao B; Ling X; Li D; Zhao J; Lv Y; Wang G; Liu X; Li N; Yang J
BMC Cancer; 2023 Jan; 23(1):103. PubMed ID: 36717797
[TBL] [Abstract][Full Text] [Related]
50. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs.
Cobleigh M; Yardley DA; Brufsky AM; Rugo HS; Swain SM; Kaufman PA; Tripathy D; Hurvitz SA; O'Shaughnessy J; Mason G; Antao V; Li H; Chu L; Jahanzeb M
Clin Cancer Res; 2020 Mar; 26(5):1105-1113. PubMed ID: 31772121
[TBL] [Abstract][Full Text] [Related]
51. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
52. Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer.
Loft M; Lok SW; De Boer R; Malik L; Greenberg S; Yeo B; Anton A; Nottage M; Wong V; Nott L; Collins IM; Torres J; Barnett F; Lombard JM; Gibbs P; Gately L
Breast Cancer Res Treat; 2023 Feb; 198(1):67-74. PubMed ID: 36624321
[TBL] [Abstract][Full Text] [Related]
53. Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
Carausu M; Carton M; Diéras V; Petit T; Guiu S; Gonçalves A; Augereau P; Ferrero JM; Levy C; Ung M; Desmoulins I; Debled M; Bachelot T; Pistilli B; Frenel JS; Mailliez A; Chevrot M; Cabel L
JAMA Netw Open; 2022 Dec; 5(12):e2247154. PubMed ID: 36520434
[TBL] [Abstract][Full Text] [Related]
54. Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients.
Wang J; Liu Y; Liang Y; Zhang Y; Dong H; Zheng T; Yu J; Du P; Jia S; King BL; Wang J; Liu X; Li H
Front Oncol; 2023; 13():1152575. PubMed ID: 37361577
[TBL] [Abstract][Full Text] [Related]
55. The Prognosis and Predictive Value of Estrogen Negative/Progesterone Positive (ER-/PR+) Phenotype: Experience of 1159 Primary Breast Cancer from a Single Institute.
Gamrani S; Boukansa S; Benbrahim Z; Mellas N; Fdili Alaoui F; Melhouf MA; Bouchikhi C; Banani A; Boubbou M; Bouhafa T; El Fatemi H
Breast J; 2022; 2022():9238804. PubMed ID: 35711896
[TBL] [Abstract][Full Text] [Related]
56. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
Wood R; Mitra D; de Courcy J; Iyer S
Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
[TBL] [Abstract][Full Text] [Related]
57. Prognostic implications of receptor discordance between primary and recurrent breast cancer.
Matsumoto A; Jinno H; Murata T; Seki T; Takahashi M; Hayashida T; Kameyama K; Kitagawa Y
Int J Clin Oncol; 2015 Aug; 20(4):701-8. PubMed ID: 25348193
[TBL] [Abstract][Full Text] [Related]
58. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
[TBL] [Abstract][Full Text] [Related]
59. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients.
Li X; Yang J; Krishnamurti U; Huo L; Ward KC; O'Regan R; Peng L
Clin Breast Cancer; 2017 Aug; 17(5):356-366. PubMed ID: 28576631
[TBL] [Abstract][Full Text] [Related]
60. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]